Timothy C. Tan

Dr. Timothy C. Tan

orcid

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2012 in Aging
Verified
Journal Article
Open access
ASAngie M. Y. Shum
Angie M. Y. Shum
TMTheodore Mahendradatta
Theodore Mahendradatta
RTRyland J. Taylor
Ryland J. Taylor
APArran B. Painter
Arran B. Painter
MMMelissa M. Moore
Melissa M. Moore
PPPatsie Polly
Patsie Polly
Cancer cachexia is a highly debilitating paraneoplastic disease observed in more than 50% of patients with advanced cancers and directly contributes to 20% of cancer deaths. Loss of skeletal muscle is a defining characteristic of patients with cancer cachexia and is associated with poor survival. The present study reveals the involvement of a myogenic transcription factor Myocyte Enhancer Factor (MEF) 2C in cancer-induced skeletal muscle wasting. Increased skeletal muscle mRNA expression of Suppressor of Cytokine Signaling (Socs) 3 and the IL-6 receptor indicative of active IL-6 signaling was seen in skeletal muscle of mice bearing the Colon 26 (C26) carcinoma. Loss of skeletal muscle structural integrity and distorted mitochondria were also observed using electron microscopy. Gene and protein expression of MEF2C was significantly downregulated in skeletal muscle from C26-bearing mice. MEF2C gene targets myozenin and myoglobin as well as myokinase were also altered during cachexia, suggesting dysregulated oxygen transport capacity and ATP regeneration in addition to distorted structural integrity. In addition, reduced expression of calcineurin was observed which suggested a potential pathway of MEF2C dysregulation. Together, these effects may limit sarcomeric contractile ability and also predispose skeletal muscle to structural instability; associated with muscle wasting and fatigue in cachexia.

9 June 2022 in Journal of the American Society of Echocardiography
Verified
Journal Article
Closed access
ABAditya Bhat
Aditya Bhat
HCHenry H.L. Chen
Henry H.L. Chen
SKShaun Khanna
Shaun Khanna
VMVipul Mahajan
Vipul Mahajan
AGArnav Gupta
Arnav Gupta
TTTimothy C. Tan
Timothy C. Tan

1 March 2021 in Circulation: Cardiovascular Quality and Outcomes
Verified
Journal Article
Closed access
PDF file
ABAditya Bhat
Aditya Bhat
SKShaun Khanna
Shaun Khanna
HCHenry H.L. Chen
Henry H.L. Chen
AGArnav Gupta
Arnav Gupta
GGGary C.H. Gan
Gary C.H. Gan
TTTimothy C. Tan
Timothy C. Tan
Atrial fibrillation (AF) is the most commonly encountered arrhythmia in clinical practice with an epidemiological coupling appreciated with advancing age, cardiometabolic risk factors, and structural heart disease. This has resulted in a significant public health burden over the years, evident through increasing rates of hospitalization and AF-related clinical encounters. The resultant gap in health care outcomes is largely twinned with suboptimal rates of anticoagulation prescription and adherence, deficits in symptom identification and management, and insufficient comorbid cardiovascular risk factor investigation and modification. In view of these shortfalls in care, the establishment of integrated chronic care models serves as a road map to best clinical practice. The expansion of integrated chronic care programs, which include multidisciplinary team care, nurse-led AF clinics, and use of telemedicine, are expected to improve AF-related outcomes in the coming years. This review will delve into current gaps in AF care and the role of integrated chronic care models in bridging fragmentations in its management.

12 October 2020 in European Journal of Clinical Investigation
Verified
Journal Article
Open access
PDF file
MMMichael Malaty
Michael Malaty
TKTahrima Kayes
Tahrima Kayes
AAAnjalee Thanuja Amarasekera
Anjalee Thanuja Amarasekera
MKMatthew Kodsi
Matthew Kodsi
CMC Raina MacIntyre
C Raina MacIntyre
TTTimothy C. Tan
Timothy C. Tan
Background The Coronavirus disease 2019 (COVID‐19) pandemic has affected millions of people worldwide resulting in significant morbidity and mortality. Arrhythmias are prevalent and reportedly, the second most common complication. Several mechanistic pathways are proposed to explain the pro‐arrhythmic effects of severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) infection. A number of treatment approaches have been trialled, each with its inherent unique challenges. This rapid systematic review aimed to examine the current incidence and available treatment of arrhythmias in COVID‐19, as well as barriers to implementation. Methods Our search of scientific databases identified relevant published studies from 1st January 2000 until 1st June 2020. We also searched Google Scholar for grey literature. We identified 1729 publications of which 1704 were excluded. Results The incidence and nature of arrhythmias in the setting of COVID‐19 was poorly documented across studies. The cumulative incidence of arrhythmia across studies of hospitalised patients was 6.9%. Drug‐induced long QT syndrome secondary to antimalarial and antimicrobial therapy was a significant contributor to arrhythmia formation, with an incidence of 14.15%. Torsades de pointes (TdP) and sudden cardiac death (SCD) was reported. Treatment strategies aim to minimise this through risk stratification and regular monitoring of corrected QT interval (QTc). Conclusion Patients with SARS‐CoV‐2 are at an increased risk of arrhythmias. Drug therapy is pro‐arrhythmogenic and may result in TdP and SCD in these patients. Risk assessment and regular QTc monitoring are imperative for safety during the treatment course. Further studies are needed to guide future decision making.

1 December 2021 in Stroke
Verified
Journal Article
Closed access
PDF file
ABAditya Bhat
Aditya Bhat
VMVipul Mahajan
Vipul Mahajan
HCHenry H.L. Chen
Henry H.L. Chen
GGGary C.H. Gan
Gary C.H. Gan
OPOctavio M. Pontes-Neto
Octavio M. Pontes-Neto
TTTimothy C. Tan
Timothy C. Tan
Ischemic stroke is a leading cause of morbidity and mortality worldwide. Embolic stroke of undetermined source has been recently proposed to categorize nonlacunar ischemic strokes without confirmed etiology after adequate investigation with a likely embolic stroke mechanism. A strategy of empirical anticoagulation for embolic stroke of undetermined source patients is attractive but may only be beneficial in a select subset of patients. Strategies which would help identify the subset of embolic stroke of undetermined source patients most likely to have cardioembolic origin of stroke, and hence benefit from anticoagulation, are needed. This article will review current evidence which may be useful in the development of a risk stratification approach based on arrhythmia monitoring, cardiac imaging, and clinical risk stratification. This approach may be beneficial in clinical practice in improving patient outcomes and reducing stroke recurrence in this population; however, further work is required with active trials underway.

21 July 2022 in European Journal of Clinical Investigation
Verified
Journal Article
Closed access
MMMichael M. Malaty
Michael M. Malaty
AAAnjalee Thanuja Amarasekera
Anjalee Thanuja Amarasekera
CLCindy Li
Cindy Li
MSMarielle Scherrer‐Crosbie
Marielle Scherrer‐Crosbie
TTTimothy C. Tan
Timothy C. Tan